Can Olaparib cure pancreatic cancer?

Olaparib may be used as single agent as first-line maintenance therapy in adults with confirmed or suspected deleterious germlineBRCA-mutated metastatic pancreatic cancer whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy (FDA orphan drug designation for this use). Before starting treatment, an FDA-approved companion diagnostic test is required to confirm the presence of specific biomarkers.

In a study of 154 patients with BRCA1 or BRCA2 mutations who had metastatic pancreatic cancer that did not worsen during at least 4 months of treatment with platinum-based chemotherapy, olaparib increased the time patients lived without disease progression: Lynparza took longer to start working, and differences with placebo were not noticed until 5 or 6 months into the trial. Patients who received olaparib lived an average of 7.4 months, with no cancer growth or recurrence during that time, while those who received a placebo lived an average of 3.8 months.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.